Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid
Authors:
- 1 August 2016
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 510 (1) , 350-358
Abstract
No abstract availableKeywords
Funding Information
- Yohei Tanaka at Sogo Pharmaceuticals for preparing the ionizable lipid
This publication has 41 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured CoreThe Journal of Physical Chemistry C, 2012
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie International Edition, 2012
- Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid CellsMolecular Therapy Nucleic Acids, 2012
- Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based MechanismsMolecular Therapy, 2010
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in miceJournal of Clinical Investigation, 2009
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences, 2007
- The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouseBiochemical and Biophysical Research Communications, 2005